Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer

Table 1 Characteristics of patients with advanced NSCLC who received nivolumab monotherapy but discontinued it for a reason other than tumor progression

Patient No.	Sex	Histological type	EGFR mutation	ALK fusion gene	Treatment regimen prior to nivolumab	Nivolumab treatment
Patient No.	Sex	Histological type	EGFR mutation	ALK fusion gene	Treatment regimen prior to nivolumab	Age at initiation (years)	ECOG PS at initiation	Number of doses	Response^a	Reason for discontinuation^b
1	F	Adenocarcinoma	wt	wt	PEM + BEV	79	1	1	NE	Bone fraction
2	M	Pleomorphic	wt	wt	CBDCA + PTX + BEV, DTX	60	1	3	PR	irAE (grade 5 encephalitis)
3	M	Adenocarcinoma	wt	wt	CBDCA + PEM	61	1	6	SD	Rejection
4	M	Squamous	wt	wt	CBDCA + PTX, VNR, CBDCA + S-1	68	0	2	PR	irAE (grade 2 pneumonitis)
5	M	NOS	wt	wt	CBDCA + PTX + TRT, PEM + BEV	55	2	1	NE	irAE (grade 2 pneumonitis)
6	M	Squamous	wt	wt	CBDCA + PTX	78	1	1	NE	irAE (grade 2 pneumonitis)
7	M	Adenosquamous	wt	wt	GEM + VNR, PEM, DTX, PEM + BEV	90	1	1	SD	Infection
8	M	Adenocarcinoma	wt	wt	CBDCA + PTX + TRT, CBDCA + PEM, DTX	75	1	31	SD	irAE (grade 2 pneumonitis)
9	M	Squamous	wt	wt	CDDP + S-1, CBDCA + nabPTX	67	1	2	PR	irAE (grade 3 dermatitis)
10	M	Adenosquamous	wt	wt	TRT, DTX	83	1	11	PR	Heart failure
11	F	Adenocarcinoma	wt	wt	PEM, DTX	79	1	8	SD	irAE (grade 3 arthritis)
12	M	Squamous	wt	wt	CBDCA + nabPTX	79	2	3	SD	irAE (grade 1 pneumonitis)
13	M	Adenocarcinoma	wt	wt	CBDCA + PEM	69	2	2	SD	irAE (grade 2 pneumonitis)
14	M	Adenocarcinoma	L858R	wt	CBDCA + PEM, Afatinib, DTX, Erlotinib + BEV, nabPTX, GEM, VNR	64	1	1	NE	irAE (grade 5 pneumonitis)
15	M	Adenocarcinoma	NE	NE	CDDP + PEM	59	1	1	NE	irAE (grade 5 pneumonitis)
16	F	Squamous	wt	wt	CBDCA + S-1	76	0	2	NE	irAE (grade 3 pneumonitis)
17	M	Squamous	NE	NE	TRT, CBDCA + S-1, VNR	68	2	5	SD	Rejection

NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, ECOG PS the Eastern Cooperative Oncology Group performance status, F female, M male, NOS not otherwise specified, wt. wild type, NE not evaluable, PEM pemetrexed, BEV bevacizumab, CBDCA carboplatin, PTX paclitaxel, DTX docetaxel, VNR vinorelbine, TRT thoracic radiotherapy, GEM gemcitabine, CDDP cisplatin, nabPTX nab-paclitaxel, PR partial response, SD stable disease, irAE immune-related adverse event
^aThe responses were classified by the Response Evaluation Criteria in Solid Tumors 1.1
^bAdverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0